Literature DB >> 19061020

RTOG criteria to evaluate acute skin reaction and its risk factors in patients with breast cancer submitted to radiotherapy.

Ana Maria Teixeira Pires1, Roberto Araujo Segreto, Helena Regina Cômodo Segreto.   

Abstract

PURPOSE: Evaluate and classify skin reactions through the Radiation Therapy Oncology Group (RTOG) criteria and characterize factors that can intervene in these reactions.
METHOD: Prospective study, with 86 women submitted to adjuvant breast radiotherapy with a total dose of 5040cGy, in a 6 MeV Linear Accelerator. Personal data were collected and breast size was measured (distance between field separation and breast height). The treated skin area was evaluated weekly.
RESULTS: Breast height and treatment technique were significant factors in the univariate analysis for the incidence of degree 3 skin reactions. However, only breast height was a significant factor in the multivariate analysis for the severity of skin reactions. The chances of occurring degree 3 reactions increase 2.61 times for each increase in height unit (cm). These findings allow nurses to plan more adequate and individualized procedures for each patient and contribute to the optimization of treatment.

Entities:  

Mesh:

Year:  2008        PMID: 19061020     DOI: 10.1590/s0104-11692008000500008

Source DB:  PubMed          Journal:  Rev Lat Am Enfermagem        ISSN: 0104-1169


  9 in total

1.  Topical use of olive oil preparation to prevent radiodermatitis: results of a prospective study in nasopharyngeal carcinoma patients.

Authors:  Zhaoyang Cui; Mei Xin; Haiying Yin; Jiandong Zhang; Fei Han
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Topical use of a silymarin-based preparation to prevent radiodermatitis : results of a prospective study in breast cancer patients.

Authors:  Martina Becker-Schiebe; Ulrich Mengs; Margitta Schaefer; Michael Bulitta; Wolfgang Hoffmann
Journal:  Strahlenther Onkol       Date:  2011-07-22       Impact factor: 3.621

3.  Emulsion of Olive Oil and Calcium Hydroxide for the Prevention of Radiation Dermatitis in Hypofractionation Post-Mastectomy Radiotherapy: A Randomized Controlled Trial.

Authors:  Imjai Chitapanarux; Napatra Tovanabutra; Siri Chiewchanvit; Patumrat Sripan; Ausareeya Chumachote; Wannapha Nobnop; Damrongsak Tippanya; Darat Khamchompoo
Journal:  Breast Care (Basel)       Date:  2019-02-05       Impact factor: 2.860

4.  Administration of TGF-ß Inhibitor Mitigates Radiation-induced Fibrosis in a Mouse Model.

Authors:  Itai Gans; Jad M El Abiad; Aaron W James; Adam S Levin; Carol D Morris
Journal:  Clin Orthop Relat Res       Date:  2021-03-01       Impact factor: 4.755

5.  In vivo skin dose measurement in breast conformal radiotherapy.

Authors:  Shokouhozaman Soleymanifard; Seyed Amir Aledavood; Atefeh Vejdani Noghreiyan; Mahdi Ghorbani; Farideh Jamali; David Davenport
Journal:  Contemp Oncol (Pozn)       Date:  2016-02-10

Review 6.  Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Oncotarget       Date:  2017-09-23

7.  Radiotherapy-Induced Skin Reactions Induce Fibrosis Mediated by TGF-β1 Cytokine.

Authors:  Cherley Borba Vieira de Andrade; Isalira Peroba Rezende Ramos; Alan César Nunes de Moraes; Ana Lúcia Rosa do Nascimento; Camila Salata; Regina Coeli Dos Santos Goldenberg; Jorge José de Carvalho; Carlos Eduardo Veloso de Almeida
Journal:  Dose Response       Date:  2017-04-28       Impact factor: 2.658

8.  Clinical factors affecting the determination of radiotherapy-induced skin toxicity in breast cancer.

Authors:  Elisa Eugenia Córdoba; Ezequiel Lacunza; Alba Mabel Güerci
Journal:  Radiat Oncol J       Date:  2021-12-24

9.  Polymorphic Variants in Oxidative Stress Genes and Acute Toxicity in Breast Cancer Patients Receiving Radiotherapy.

Authors:  Elisa Eugenia Córdoba; Martín Carlos Abba; Ezequiel Lacunza; Eduardo Fernánde; Alba Mabel Güerci
Journal:  Cancer Res Treat       Date:  2016-01-14       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.